Alteon's Investigational Drug Alagebrium Demonstrates Beneficial Effects on Heart and Kidney in Preclinical Studies
May 24 2004 - 1:54PM
PR Newswire (US)
Alteon's Investigational Drug Alagebrium Demonstrates Beneficial
Effects on Heart and Kidney in Preclinical Studies Abstract
Presented at the American Society of Hypertension Annual Meeting;
Paper Published in the American Journal of Hypertension PARSIPPANY,
N.J., May 24 /PRNewswire-FirstCall/ -- Alteon Inc. announced today
that an abstract detailing the effects of Alteon's A.G.E. Crosslink
Breaker alagebrium (formerly ALT-711) in the treatment of aged
spontaneously hypertensive rats was presented on Saturday at the
American Society of Hypertension Nineteenth Annual Scientific
Meeting and Exposition in New York City. In addition, the abstract
and a separate paper were recently published in the American
Journal of Hypertension. Study results showed that alagebrium
therapy demonstrated beneficial cardiovascular and renal effects by
reducing systolic blood pressure, left ventricular mass and urinary
protein excretion, as well as improving left ventricular (LV)
function and aortic distensibility. "Breaker of glycated collagen
cross-links, ALT-711, improves left ventricular function and aortic
distensibility in elderly spontaneously hypertensive rats," was
conducted by researchers from the Hypertension Research Laboratory,
Ochsner Clinic Foundation in New Orleans, LA. The abstract noted:
-- That treatment with alagebrium reduced aortic stiffness as
compared to placebo, as indicated by increased aortic
distensibility (108 +/- 9 mm/mm Hg vs. 79 +/- 8; p
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jul 2023 to Jul 2024